NMN has been well tolerated in human trials at doses up to 1,250 mg daily, with no serious adverse events reported. But the longest trial ran just 12 weeks, and as of a July 2026 notice, the FSSAI lists NMN as an unapproved supplement ingredient in India.
NMN raises NAD+ in human blood. That much is settled. Two meta-analyses published in 2025 looked at overlapping trials and reached opposite conclusions about gait speed, and FSSAI has called NMN an unapproved ingredient for supplements in India.
Why most Indian diets fall short for healthy ageing, the protein gap almost nobody is addressing, common nutrition myths that quietly cause harm, and what actually works for Indians eating Indian food.
Why ageing speeds up after 40 in Indians: See how NAD+ decline triggers a symptoms of fatigue, brain fog, muscle loss & heart weakness - and how NMN can help.